Literature DB >> 6880634

Visual ability and drug regimen: relation to compliance with glaucoma therapy.

P A Granström, S Norell.   

Abstract

Compliance with pilocarpine eye drop therapy was studied in relation to different measures of visual ability and different features of the drug regimen. Neither visual ability, nor complexity of the drug regimen nor side effects were significantly related to the patients' compliance with their pilocarpine therapy. Nevertheless, non-compliance was significantly more common among patients who regarded the eye drops as very unpleasant than among patients who did not. This indicates that non-compliance is related to the patient's perception of side effects and/or negative attitudes to the treatment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6880634     DOI: 10.1111/j.1755-3768.1983.tb01414.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  4 in total

1.  Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

Authors:  A L Robin; R Ritch; D Shin; B Smythe; T Mundorf; R P Lehmann
Journal:  Trans Am Ophthalmol Soc       Date:  1995

2.  Drug attitude and adherence to anti-glaucoma medication.

Authors:  Samin Hong; Sung Yong Kang; Jong Uk Yoon; Uicheon Kang; Gong Je Seong; Chan Yun Kim
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

3.  Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review.

Authors:  Gregory Reardon; Sameer Kotak; Gail F Schwartz
Journal:  Patient Prefer Adherence       Date:  2011-09-23       Impact factor: 2.711

4.  Noncompliance with Ocular Hypertensive Treatment in Patients with Primary Open Angle Glaucoma among the Arab Population in Israel: A Cross-Sectional Descriptive Study.

Authors:  Muhannad Masoud; Adi Sharabi-Nov; Joseph Pikkel
Journal:  J Ophthalmol       Date:  2013-07-01       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.